This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
REGNPositive Net Change SNYNegative Net Change BIIBNegative Net Change BMYNegative Net Change
biotechnology biotechs
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
by Zacks Equity Research
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
BMYNegative Net Change MRKNegative Net Change GERNNegative Net Change ALKSNegative Net Change
biotechnology pharmaceuticals
Northwest Pipe Co. (NWPX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NWPXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
by Zacks Equity Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
BMYNegative Net Change MRKNegative Net Change EXELNegative Net Change
biotechnology pharmaceuticals
Livent (LTHM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
LTHMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
by Zacks Equity Research
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
PFENegative Net Change MRNAPositive Net Change OCGNPositive Net Change BNTXNegative Net Change
biotechnology biotechs pharmaceuticals
Company News for May 24, 2022
by Zacks Equity Research
Companies In The News Are: JPM, VMW, AVGO, EA, EBS.
JPMPositive Net Change VMWPositive Net Change AVGOPositive Net Change EAPositive Net Change EBSNegative Net Change
biotechnology consumer-discretionary finance tech-stocks
Healthcare Outperformance May Signal Short-Term Market Bottom
by Bryan Hayes
This sector outperformance may be a sign the market is nearing a point of selling exhaustion.
JNJNegative Net Change XLVNegative Net Change
biotechnology biotechs cancer coronavirus dividend-investing dividends earnings etfs investing large-cap pharmaceuticals
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
by Zacks Equity Research
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
REGNPositive Net Change GERNNegative Net Change ALKSNegative Net Change BAYRYNegative Net Change
biotechnology pharmaceuticals
After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SVRAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hersha Hospitality (HT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma
by Zacks Equity Research
Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog
APLTPositive Net Change BOLTPositive Net Change
biotechnology medical oncology-screening
Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
by Zacks Equity Research
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
RHHBYNegative Net Change GILDNegative Net Change RCUSPositive Net Change
biotechnology medical pharmaceuticals
Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News
by Ekta Bagri
Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
REGNPositive Net Change VRTXNegative Net Change ICPTPositive Net Change BHVNNegative Net Change
biotechnology medical pharmaceuticals
Should You Buy Chemours (CC) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Valmont Industries (VMI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VMIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
VRTXNegative Net Change CLVSPositive Net Change GBTPositive Net Change VYGRPositive Net Change
biotechnology biotechs earnings pharmaceuticals
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
VRTXNegative Net Change FATEPositive Net Change VYGRPositive Net Change
biotechnology earnings pharmaceuticals
Should You Buy Penske Automotive (PAG) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PAGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Best Profitable Stocks to Buy Using Net Income Ratio
by Tirthankar Chakraborty
Xencor (XNCR), Encore Wire (WIRE) & Silvergate Capital (SI) have been selected as the top profitable picks with a high net income ratio.
SINegative Net Change WIREPositive Net Change XNCRPositive Net Change
biotechnology biotechs finance
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
by Zacks Equity Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
BIIBNegative Net Change BMYNegative Net Change AMGNNegative Net Change GILDNegative Net Change VRTXNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology earnings pharmaceuticals
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week
by Nalak Das
Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.
HSTPositive Net Change VRTXNegative Net Change CINegative Net Change EOGPositive Net Change BGNEPositive Net Change
biotechnology insurance oil-energy pharmaceuticals reit
Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.
VRTXNegative Net Change JAZZNegative Net Change CLVSPositive Net Change ONTXNo Net Change
biotechnology earnings
Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.
REGNPositive Net Change SNYNegative Net Change VRTXNegative Net Change CLVSPositive Net Change
biotechnology